Increasing tumor uptake of anticancer drugs with imatinib

Seminars in Oncology

Volumn 31, Issue SUPPL. 6, 2004, Pages 18-23

  Pietras, Kristian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CELL TYPE; CHEMOTHERAPY; CLINICAL TRIAL; DRUG UPTAKE; HUMAN; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TISSUE PRESSURE; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; EXTRACELLULAR FLUID; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; EXTRACELLULAR FLUID; HUMANS; NEOPLASMS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 3042714173     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.036     Document Type: Article

References (38)

1. Broxterman H.J., Lankelma J., Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents similarities and differences. Drug Resist Updat. 6:2003;111-127
2. Jain R.K. Transport of molecules in the tumor interstitium A review. Cancer Res. 47:1987;3039-3051
3. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 46:2001;149-168
4. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 79:1999;1283-1316
5. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104
6. Buchdunger E., O'Reilly T., Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 38:(suppl 5):2002;S28-S36
7. Savage D.G., Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 346:2002;683-693
8. Capdeville R., Buchdunger E., Zimmermann J., et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 1:2002;493-502
9. Aukland K., Reed R.K. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 73:1993;1-78
10. Reed R.K., Berg A., Gjerde E.A., et al. Control of interstitial fluid pressure Role of beta1-integrins. Semin Nephrol. 21:2001;222-230
11. Meyer F.A., Laver-Rudich Z., Tanenbaum R. Evidence for a mechanical coupling of glycoprotein microfibrils with collagen fibrils in Wharton's jelly. Biochim Biophys Acta. 755:1983;376-387
12. Wiig H., Rubin K., Reed R.K. New and active role of the interstitium in control of interstitial fluid pressure Potential therapeutic consequences. Acta Anaesthesiol Scand. 47:2003;111-121
13. Lund T., Wiig H., Reed R.K. Acute postburn edema Role of strongly negative interstitial fluid pressure. Am J Physiol. 255:1988;H1069-H1074
14. Reed R.K., Rubin K., Wiig H., et al. Blockade of beta 1-integrins in skin causes edema through lowering of interstitial fluid pressure. Circ Res. 71:1992;978-983
15. Gullberg D., Tingstrom A., Thuresson A.C., et al. Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res. 186:1990;264-272
16. Rodt S.Å., Åhlén K., Berg A., et al. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J Physiol. 495:1996;193-200
17. Heuchel R., Berg A., Tallquist M., et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc Natl Acad Sci U S A. 96:1999;11410-11415
18. Willett C.G., Boucher Y., Di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:2004;145-147
19. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570
20. Brekken C., Bruland O.S., de Lange Davies C. Interstitial fluid pressure in human osteosarcoma xenografts significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res. 20:2000;3503-3512
21. Stohrer M., Boucher Y., Stangassinger M., et al. Oncotic pressure in solid tumors is elevated. Cancer Res. 60:2000;4251-4255
22. Rubin K., Sjoquist M., Gustafsson A.M., et al. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer. 86:2000;636-643
23. Curnis F., Sacchi A., Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 110:2002;475-482
24. Brekken C., Hjelstuen M.H., Bruland O.S., et al. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res. 20:2000;3513-3519
25. Curti B.D., Urba W.J., Alvord W.G., et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients Changes during treatment. Cancer Res. 53:1993;2204-2207
26. Milosevic M., Fyles A., Hedley D., et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 61:2001;6400-6405
27. Maier U., Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer Randomized trial. J Urol. 141:1989;529-530
28. Pillwein K., Fuiko R., Slavc I., et al. Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett. 131:1998;101-108
29. Pietras K., Sjöblom T., Rubin K., et al. PDGF receptors as cancer drug targets. Cancer Cell. 3:2003;439-443
30. LaRochelle W.J., Jeffers M., Corvalan J.R., et al. Platelet-derived growth factor D Tumorigenicity in mice and dysregulated expression in human cancer. Cancer Res. 62:2002;2468-2473
31. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710
32. Li H., Fredriksson L., Li X., et al. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 22:2003;1501-1510
33. Cao R., Brakenhielm E., Li X., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 16:2002;1575-1583
34. Pietras K., Ostman A., Sjoquist M., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2001;2929-2934
35. Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62:2002;5476-5484
36. Pietras K., Stumm M., Hubert M., et al. STI571 Enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res. 9:2003;3779-3787
37. Wiig H., Tveit E., Hultborn R., et al. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest. 42:1982;159-164
38. Jain R.K. Molecular regulation of vessel maturation. Nat Med. 9:2003;685-693